Compare TTE & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTE | JNJ |
|---|---|---|
| Founded | 1924 | 1886 |
| Country | France | United States |
| Employees | 101513 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.5B | 542.4B |
| IPO Year | N/A | 2003 |
| Metric | TTE | JNJ |
|---|---|---|
| Price | $78.70 | $240.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 20 |
| Target Price | $76.63 | ★ $238.20 |
| AVG Volume (30 Days) | 1.4M | ★ 7.4M |
| Earning Date | 04-29-2026 | 04-14-2026 |
| Dividend Yield | ★ 4.14% | 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $28.83 | $6.63 |
| Revenue Next Year | N/A | $7.43 |
| P/E Ratio | ★ $12.60 | $111.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.40 | $151.01 |
| 52 Week High | $94.17 | $251.71 |
| Indicator | TTE | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 21.90 | 60.83 |
| Support Level | $76.56 | $233.83 |
| Resistance Level | $82.21 | $244.80 |
| Average True Range (ATR) | 1.44 | 4.73 |
| MACD | -0.93 | 0.53 |
| Stochastic Oscillator | 3.62 | 86.93 |
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2025, it produced 1.5 million barrels of liquids and 5.4 billion cubic feet of natural gas per day. At the end of 2025, reserves stood at 11.2 billion barrels of oil equivalent, 55% of which are liquids. During 2025, it had LNG sales of 43.9 million metric tons. The company owns interests in refineries with a capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 34 gigawatts.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.